On March 3, 2021, the Food and Drug Administration (FDA) granted regular approval to lorlatinib for patients with metastatic NSCLC whose tumors are ALK-positive, detected by an FDA-approved test (18). The gene discussed is ALK; the disease is non-small cell lung carcinoma.